Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes.

Cheema A, Weber J, Strosberg JR.

Ann Surg Oncol. 2012 Sep;19(9):2932-6. doi: 10.1245/s10434-012-2285-7.

PMID:
22350605
2.

Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.

Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, Kvols LK.

Ann Surg. 2012 Aug;256(2):321-5. doi: 10.1097/SLA.0b013e31824e6108.

PMID:
22415420
3.

Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors.

Crippa S, Partelli S, Zamboni G, Scarpa A, Tamburrino D, Bassi C, Pederzoli P, Falconi M.

Surgery. 2014 Jan;155(1):145-53. doi: 10.1016/j.surg.2013.08.002.

PMID:
24646958
4.

Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.

Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK.

J Clin Oncol. 2013 Feb 1;31(4):420-5. doi: 10.1200/JCO.2012.44.5924.

PMID:
23248248
5.

Renal cell carcinoma: prognostic significance of incidentally detected tumors.

Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A.

J Urol. 2000 Feb;163(2):426-30.

PMID:
10647646
6.

Incidentally, it's still cancer.

Vollmer CM Jr.

Arch Surg. 2011 May;146(5):539. No abstract available.

PMID:
21739652
7.

Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).

Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.

Am J Clin Oncol. 2012 Dec;35(6):549-56. doi: 10.1097/COC.0b013e31821dee0f.

PMID:
21659833
8.

Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.

Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK.

J Clin Oncol. 2011 Aug 1;29(22):3044-9. doi: 10.1200/JCO.2011.35.1817.

PMID:
21709192
9.

Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE.

J Gastrointest Surg. 2010 May;14(5):891-8. doi: 10.1007/s11605-010-1173-3.

PMID:
20224984
10.

Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.

Morin E, Cheng S, Mete O, Serra S, Araujo PB, Temple S, Cleary S, Gallinger S, Greig PD, McGilvray I, Wei A, Asa SL, Ezzat S.

Cancer Med. 2013 Oct;2(5):701-11. doi: 10.1002/cam4.96.

11.

Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis.

Birnbaum DJ, Gaujoux S, Cherif R, Dokmak S, Fuks D, Couvelard A, Vullierme MP, Ronot M, Ruszniewski P, Belghiti J, Sauvanet A.

Surgery. 2014 Jan;155(1):13-21. doi: 10.1016/j.surg.2013.08.007.

PMID:
24238123
12.

Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.

Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernández-del Castillo C.

Arch Surg. 2011 May;146(5):534-8. doi: 10.1001/archsurg.2011.102.

13.

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.

Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G, Wiedenmann B.

Cancer. 2008 Jul 15;113(2):256-65. doi: 10.1002/cncr.23549.

14.

Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.

Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS.

J Am Coll Surg. 2007 Oct;205(4):558-63.

PMID:
17903729
15.

TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.

Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, La Rosa S, Luong TV, Pape U, Perren A, Ruszniewski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B.

J Natl Cancer Inst. 2012 May 16;104(10):764-77. doi: 10.1093/jnci/djs208.

16.

Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?

Fitzgerald TL, Dennis SO, Kachare SD, Vohra NA, Zervos EE.

Surgery. 2015 Aug;158(2):466-71. doi: 10.1016/j.surg.2015.03.042.

PMID:
26013986
17.

Is the new classification of neuroendocrine pancreatic tumors of clinical help?

Schindl M, Kaczirek K, Kaserer K, Niederle B.

World J Surg. 2000 Nov;24(11):1312-8.

PMID:
11038199
18.

Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.

Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E.

Scand J Gastroenterol. 2014 Jun;49(6):734-41. doi: 10.3109/00365521.2014.903432.

PMID:
24679166
19.

Incidental detection of renal cell carcinoma is an independent prognostic marker: results of a long-term, whole population study.

Palsdottir HB, Hardarson S, Petursdottir V, Jonsson A, Jonsson E, Sigurdsson MI, Einarsson GV, Gudbjartsson T.

J Urol. 2012 Jan;187(1):48-53. doi: 10.1016/j.juro.2011.09.025.

PMID:
22088336
20.

Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors.

Chen MH, Yeh YC, Shyr YM, Jan YH, Chao Y, Li CP, Wang SE, Tzeng CH, Chang PM, Liu CY, Chen MH, Hsiao M, Huang CY.

J Gastroenterol. 2013 Jan;48(1):101-8. doi: 10.1007/s00535-012-0614-z.

PMID:
22706573
Items per page

Supplemental Content

Support Center